Sareh Keshavarzi
Overview
Explore the profile of Sareh Keshavarzi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
490
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Chahal D, Sharma D, Keshavarzi S, Arisar F, Patel K, Xu W, et al.
Hepatol Int
. 2022 Feb;
16(2):325-336.
PMID: 35178663
Background: Lean NAFLD may differ from NAFLD found in overweight or obese patients. We used the UK biobank to conduct a cross-sectional study that examined features that distinguish lean NAFLD...
12.
Cheung P, Patel S, North S, Sahgal A, Chu W, Soliman H, et al.
Eur Urol
. 2021 Aug;
80(6):693-700.
PMID: 34399998
Background: Despite the paucity of prospective evidence, stereotactic radiotherapy (SRT) is increasingly being considered in the setting of oligoprogression to delay the need to change systemic therapy. Objective: To determine...
13.
Construct Validity of the EuroQoL-5 Dimension and the Health Utilities Index in Head and Neck Cancer
Noel C, Keshavarzi S, Forner D, Stephens R, Watson E, Monteiro E, et al.
Otolaryngol Head Neck Surg
. 2021 Jul;
166(5):877-885.
PMID: 34311628
Objective: The objective of this study was to evaluate the construct validity of 2 health utility instruments-the EuroQoL-5 Dimension (EQ-5D) and the Health Utilities Index-Mark 3 (HUI-3)-and to compare them...
14.
Araujo D, Muniz T, Yang A, Keshavarzi S, Sorotsky H, Butler M, et al.
Curr Oncol
. 2021 Jul;
28(3):2173-2179.
PMID: 34208089
Background And Aims: Current guidelines state that infliximab is contraindicated for the treatment of immune checkpoint inhibitor-related hepatitis (ir-hepatitis) due to the risk of inducing further liver damage. As this...
15.
Burgener J, Zou J, Zhao Z, Zheng Y, Shen S, Huang S, et al.
Clin Cancer Res
. 2021 Jun;
27(15):4230-4244.
PMID: 34158359
Purpose: Circulating tumor DNA (ctDNA) enables personalized treatment strategies in oncology by providing a noninvasive source of clinical biomarkers. In patients with low ctDNA abundance, tumor-naïve methods are needed to...
16.
McCuaig J, Thain E, Malcolmson J, Keshavarzi S, Randall Armel S, Kim R
Curr Oncol
. 2021 Apr;
28(2):1459-1471.
PMID: 33917963
This study compares knowledge, experience and understanding of genetic testing, and psychological outcomes among breast and ovarian cancer patients undergoing multi-gene panel testing via genetic counselor-mediated (GMT) or oncologist-mediated (OMT)...
17.
Bebu I, Keshavarzi S, Gao X, Braffett B, Canty A, Herman W, et al.
Diabetes Care
. 2021 Apr;
44(6):1309-1316.
PMID: 33883194
Objective: The role of genetic factors in the risk of cardiovascular disease (CVD) for patients with type 1 diabetes (T1D) remains unknown. We therefore examined whether previously identified genetic factors...
18.
Keshavarzi S, Braffett B, Pop-Busui R, Orchard T, Soliman E, Lorenzi G, et al.
Diabetes Care
. 2021 Feb;
44(5):1125-1132.
PMID: 33632724
Objective: Individuals with diabetes have higher resting heart rate compared with those without, which may be predictive of long-term cardiovascular disease (CVD) risk. Using data from the Diabetes Control and...
19.
Huang S, de Almeida J, Watson E, Glogauer M, Xu W, Keshavarzi S, et al.
Head Neck
. 2020 Oct;
43(2):456-466.
PMID: 33058305
Background: We aimed to compare unstimulated saliva flow using 3-minute modified Schirmer test (MST) following bilateral vs unilateral radiotherapy (RT) in oropharyngeal carcinoma (OPC). Methods: We reviewed OPC patients treated...
20.
McDowell L, So N, Keshavarzi S, Xu W, Rock K, Chan B, et al.
Oral Oncol
. 2020 Jul;
109:104865.
PMID: 32679542
Objectives: Sexual health problems have been identified as an unmet need in head and neck cancer (HNC) survivors. In particular, little is known about such outcomes in survivors of nasopharyngeal...